Mitochondria-targeted peptides (SS-31/Bendavia) reduced myocardial infarct size by up to 60% in rats when given before or during reperfusion — demonstrating potent cardioprotection through mitochondrial protection.
Key findingMitochondria-targeted peptides (SS-31 and analogs) reduced myocardial infarct size by up to 60% in rat ischemia-reperfusion, with efficacy when given
What the researchers found
Mitochondria-targeted peptides (SS-31 and analogs) reduced myocardial infarct size by up to 60% in rat ischemia-reperfusion, with efficacy when given before ischemia or at reperfusion — demonstrating potent cardioprotection through preservation of mitochondrial function.
Why it matters
Relevant for opioid-peptides, cardiovascular, neuroprotection.
How the study worked
animal-study study on opioid-peptides, cardiovascular.
What this study cannot tell us
See abstract.
How to read the evidence
moderate evidence.
When this study was published
Published in 2007.
The bigger picture
Advances peptide research.
Questions still open
- Further research needed.
- Clinical translation to evaluate.
Common questions
What was studied?
What was found?
Read the original research
Potent mitochondria-targeted peptides reduce myocardial infarction in rats.
Coronary artery disease, 18(3), 215-20
Citation
Cho, Janghyun; Won, Kyungheon; Wu, DunLi; Soong, Yi; Liu, Shaoyi; Szeto, Hazel H; Hong, Mun K. (2007). Potent mitochondria-targeted peptides reduce myocardial infarction in rats.. Coronary artery disease, 18(3), 215-20.